Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Ephedra-containing dietary supplement across-the-board label warning suggested by FDA.

This article was originally published in The Tan Sheet

Executive Summary

EPHEDRA SUPPLEMENT ACROSS-THE-BOARD LABEL WARNING STATEMENT would be required for all dietary supplements containing ephedrine alkaloids under a June 4 FDA proposed rule. The warning statement advises consumers to consult a "health care provider" before using ephedrine alkaloid-containing products if they are pregnant or nursing or have: heart disease; thyroid disease; diabetes; high blood pressure; depression or other psychiatric condition; glaucoma; difficulty in urinating; prostate enlargement; or a seizure disorder.

You may also be interested in...



Ephedra “Black Box” Warning Considered By FDA

FDA is suggesting that a "black box" warning appear on the principal display panel of all ephedrine alkaloid-containing dietary supplements, FDA Commissioner Mark McClellan, MD/PhD, said during a Feb. 28 briefing held in Washington, D.C

Ephedra “Black Box” Warning Considered By FDA

FDA is suggesting that a "black box" warning appear on the principal display panel of all ephedrine alkaloid-containing dietary supplements, FDA Commissioner Mark McClellan, MD/PhD, said during a Feb. 28 briefing held in Washington, D.C

Ephedra “Black Box” Warning Considered By FDA

FDA is suggesting that a "black box" warning appear on the principal display panel of all ephedrine alkaloid-containing dietary supplements, FDA Commissioner Mark McClellan, MD/PhD, said during a Feb. 28 briefing held in Washington, D.C

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS087146

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel